Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer |
Yuan, Zhi-Jun
(Medical Department of Veteran Cadre, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University)
Zhou, Wen-Wu (Department of Thoracic Surgery, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University) Liu, Wei (Medical Department of Veteran Cadre, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University) Wu, Bai-Ping (Molecular Biology Laboratory, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University) Zhao, Jin (Molecular Biology Laboratory, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University) Wu, Wei (Medical Department of Veteran Cadre, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University) He, Yi (Medical Department of Veteran Cadre, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University) Yang, Shuo (Medical Department of Veteran Cadre, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University) Su, Jing (Medical Department of Veteran Cadre, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University) Luo, Yi (Medical Department of Veteran Cadre, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University) |
1 | Allen WL, Johnston PG (2005). Role of genomic markers in colorectal cancer treatment. J Clin Oncol, 23, 4545-52. DOI |
2 | Booton R, Ward T, Heighway J, et al (2006). Glutathione-Stransferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer. J Thorac Oncol, 1, 679-83. DOI |
3 | Chu T, Bunce K, Hogge WA, et al (2009). Statistical model for whole genome sequencing and its application to minimally invasive diagnosis of fetal genetic disease. Bioinformatics, 25, 1244-50. DOI |
4 | De Luca A, Pellizzari Tregno F, Sau A, et al (2013). Glutathione S-transferase P1-1 as a target for mesothelioma treatment. Cancer Sci, 104, 223-30. DOI |
5 | Dong X, Hao Y, Wei Y, et al (2014). Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression. PLoS One, 9, 92320. DOI |
6 | Fuertes MA, Castilla J, Alonso C, et al (2003). Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem, 10, 257-66. DOI |
7 | Gray J, Simon G, Bepler G (2007). Molecular predictors of chemotherapy response in non-small-cell lung cancer. Expert Rev Anticancer Ther, 7, 545-9. DOI |
8 | Kabler SL, Seidel A, Jacob J, et al (2009). Differential protection by human glutathione S-transferase P1 against cytotoxicity of benzo[a]pyrene, dibenzo[a,l]pyrene, or their dihydrodiol metabolites, in bi-transgenic cell lines that co-express rat versus human cytochrome P4501A1. Chem Biol Interact, 179, 240-6. DOI |
9 | Li Y, Wang LR, Chen J, et al (2014). First-line gemcitabine plus cisplatin in non-small cell lung cancer patients. Dis Markers, 2014, 960458. |
10 | Lu C, Spitz MR, Zhao H, et al (2006). Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced non-small cell lung carcinoma. Cancer, 106, 441-7. DOI ScienceOn |
11 | Lv HY, Li QC, Wei HJ, et al (2012). Relationship between GSTP1 and XPG genetic polymorphisms and survival of platinum-based chemotherapy in advanced non-small cell lung cancer patients. China Oncology, 22, 609-17. |
12 | Nakahira S, Nakamori S, Tsujie M, et al (2007). Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer, 120, 1355-63. DOI ScienceOn |
13 | Ou C, Zhu B, Zhao HL, et al (2015). Association of glutathione S-transferase P1 gene polymorphism with the risk of smallcell carcinoma of lungcancer. J Recept Signal Transduct Res, 35, 165-9. DOI |
14 | Parker LJ, Italiano LC, Morton CJ, et al (2011). Studies of glutathione transferase P1-1 bound to a platinum(IV)-based anticancer compound reveal the molecular basis of its activation. Chemistry, 17, 7806-16. DOI |
15 | Peklak-Scott C, Smitherman PK, Townsend AJ, et al (2008). Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther, 7, 3247-55. DOI ScienceOn |
16 | Qiu ZQ, Zhao K (2014). Expression of ERCC1, RRM1 and LRP in non-small cell lung cancers and their influence on chemotherapeutic efficacy of gemcitabine concomitant with nedaplatin. Asian Pac J Cancer Prev, 15, 7303-7. DOI |
17 | Rodriguez J, Boni V, Hernández A, et al (2011). Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy. Eur J Cancer, 47, 839-47. DOI |
18 | Sun N, Sun X, Chen B, et al (2010). MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol, 65, 437-46. DOI |
19 | Sharma R, Ellis B, Sharma A (2011). Role of alpha class glutathione transferases (GSTs) in chemoprevention: GSTA1 and A4 overexpressing human leukemia (HL60) cells resist sulforaphane and curcumin induced toxicity. Phytother Res, 25, 563-8. DOI |
20 | Singh S (2015). Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death. Cancer Chemother Pharmacol, 75, 1-15. DOI |
21 | Wang LR, Huang MZ, Zhang GB, et al (2007). Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol, 60, 601-7. DOI |
22 | Wang L, Wu X, Huang M, et al (2007). The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol, 60, 211-8. DOI |
23 | Zhang GB, Chen J, Wang LR, et al (2012). RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer. Cancer Chemother Pharmacol, 69, 1277-87. DOI |
24 | Zhang X, Jin FS, Zhang LG, et al (2013). Predictive and prognostic roles of ribonucleotide reductase M1 in patients with pancreatic cancer treated with gemcitabine: a metaanalysis. Asian Pac J Cancer Prev, 14, 4261-5. DOI |
25 | Zhang Y, Yu L, Xia N (2014). Effect of Brucea Javanica Oil Emulsion combined with GP regimen on the immune function of patients with advanced non-small cell lung cancer. J Int Transl Med, 2, 262-5. |
26 | Zhou F, Yu Z, Jiang T, et al (2011). Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. Swiss Med Wkl, 141, 13275. |